Literature DB >> 10792848

Distinct innate and acquired immune responses to Leishmania in putative susceptible and resistant human populations endemically exposed to L. (Viannia) panamensis infection.

F Bosque1, N G Saravia, L Valderrama, G Milon.   

Abstract

Mechanisms of constitutive and acquired susceptibility/resistance to Leishmania Viannia panamensis (L. (V ) p.) were investigated in endemically exposed human populations presenting either recurrent disease (putative susceptible) or subclinical infection (clinically resistant). Cutaneous delayed type hypersensitivity response to leishmanin was significantly lower among individuals experiencing recurrent leishmaniasis than among those whose skin test converted without developing the disease. Monocyte derived macrophages from individuals with recurrent disease were more permissive in vitro to the entry of parasites than macrophages from subclinically infected individuals. In vitro proliferation of CD4 and CD8 T lymphocytes in response to intracellular amastigotes was significantly lower among individuals with a history of recurrent disease compared with subclinically infected individuals. Linear regression analyses revealed a strong direct relationship between the production of interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and interleukin (IL)-10 by peripheral blood mononuclear cells (PBMC) from resistant (subclinically infected) individuals and no correlation in the production of these cytokines by PBMC from individuals who experienced recurrent disease. The results provide evidence of differences in the innate and acquired responses to Leishmania according to the outcome of the natural infection. These findings support the feasibility of identifying the immunological bases of innate and acquired resistance through studies in naturally exposed human populations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792848     DOI: 10.1046/j.1365-3083.2000.00724.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  29 in total

1.  Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis.

Authors:  Carolina Gallego; Douglas Golenbock; Maria Adelaida Gomez; Nancy Gore Saravia
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

2.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

3.  Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

Authors:  P Tripathi; S Ray; S Sunder; A Dube; S Naik
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  T-bet, GATA-3, and Foxp3 expression and Th1/Th2 cytokine production in the clinical outcome of human infection with Leishmania (Viannia) species.

Authors:  Yira Rosalba Díaz; Ricardo Rojas; Liliana Valderrama; Nancy Gore Saravia
Journal:  J Infect Dis       Date:  2010-08-15       Impact factor: 5.226

5.  Inflammasome-derived IL-1β production induces nitric oxide-mediated resistance to Leishmania.

Authors:  Djalma S Lima-Junior; Diego L Costa; Vanessa Carregaro; Larissa D Cunha; Alexandre L N Silva; Tiago W P Mineo; Fredy R S Gutierrez; Maria Bellio; Karina R Bortoluci; Richard A Flavell; Marcelo T Bozza; João S Silva; Dario S Zamboni
Journal:  Nat Med       Date:  2013-06-09       Impact factor: 53.440

6.  Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.

Authors:  Thiago Marconi Cardoso; Álvaro Machado; Diego Luiz Costa; Lucas P Carvalho; Adriano Queiroz; Paulo Machado; Phillip Scott; Edgar M Carvalho; Olívia Bacellar
Journal:  Infect Immun       Date:  2014-12-22       Impact factor: 3.441

7.  Immunopathological characterization of human cutaneous leishmaniasis lesions caused by Leishmania (Viannia) spp. in Amazonian Brazil.

Authors:  Cláudia Maria Castro Gomes; Maria Gloria Teixeira Sousa; Joyce Prieto Bezerra Menezes; Marliane Campos Batista; Ana Carolina Stocco Lima; Walter Belda; Daniel Bradshaw; Monica Elinor Alves Gama; Márcia Dalastra Laurenti; Fernando Tobias Silveira; Carlos Eduardo Pereira Corbett
Journal:  Parasitol Res       Date:  2017-02-21       Impact factor: 2.289

8.  Asymptomatic Leishmania infection: a new challenge for Leishmania control.

Authors:  Om Prakash Singh; Epco Hasker; David Sacks; Marleen Boelaert; Shyam Sundar
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

9.  Immunologic Markers of Protection in Leishmania (Viannia) braziliensis Infection: A 5-Year Cohort Study.

Authors:  Aline C Muniz; Olívia Bacellar; Ednaldo Lima Lago; Augusto M Carvalho; Pedro Paulo Carneiro; Luiz Henrique Guimarães; Paulo N Rocha; Lucas P Carvalho; Marshall Glesby; Edgar M Carvalho
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

10.  Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?

Authors:  A Gomes-Silva; R de Cássia Bittar; R Dos Santos Nogueira; V S Amato; M da Silva Mattos; M P Oliveira-Neto; S G Coutinho; A M Da-Cruz
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.